Drug Trial Radar · NCT06505551
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Oct 2024
Primary completion
Dec 2026
Study completion Dec 2028
Sponsor
- Lead sponsor
- SCG Cell Therapy Pte. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited to combination chemotherapy and/or combination chemo-immunotherapy
Conditions
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Cervical Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vaginal Squamous Cell Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Head and Neck Cancer
Interventions
SCG142Biological
Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy
CyclophosphamideDrug
for 3 consecutive days
FludarabineDrug
for 3 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (Phase 1)Time frame: 2 years
- Objective response rate (ORR) (Phase 2)Time frame: 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.